A5011059993- Platelet Disorders and Treatments
- Blood groups and transfusion
- Chronic Lymphocytic Leukemia Research
- Autoimmune Bullous Skin Diseases
- Cell death mechanisms and regulation
- Immunodeficiency and Autoimmune Disorders
- Neutropenia and Cancer Infections
- Renal Diseases and Glomerulopathies
- Lymphoma Diagnosis and Treatment
- Immune Response and Inflammation
- Acute Myeloid Leukemia Research
- Blood disorders and treatments
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Blood properties and coagulation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- RNA Interference and Gene Delivery
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Cell Adhesion Molecules Research
- Cancer-related Molecular Pathways
- Chronic Myeloid Leukemia Treatments
- Immunotherapy and Immune Responses
- Ubiquitin and proteasome pathways
Queen Mary University of London
2012-2024
Royal London Hospital
2010-2021
Barts Health NHS Trust
1989-2021
National Health Service
2011-2019
GTx (United States)
2017
Hyundai Mobis (South Korea)
2017
National Institute for Health and Care Excellence
2012-2014
Weatherford College
2013
British Society for Haematology
2010
University Hospital Crosshouse
2010
Over the last decade, there have been numerous developments and changes in treatment practices for management of patients with immune thrombocytopenia (ITP). This article is an update International Consensus Report published 2010. A critical review was performed to identify all relevant articles between 2009 2018. An expert panel screened, reviewed, graded studies formulated updated consensus recommendations based on new data. The final document provides diagnosis ITP adults, during...
BackgroundLimits on the frequency of whole blood donation exist primarily to safeguard donor health. However, there is substantial variation across services in maximum donations allowed. We compared standard practice UK with shorter inter-donation intervals used other countries.MethodsIn this parallel group, pragmatic, randomised trial, we recruited donors aged 18 years or older from 25 centres England, UK. By use a computer-based algorithm, men were randomly assigned (1:1:1) 12-week...
Summary Romiplostim was effective, safe, and well‐tolerated over 6–12 months of continuous treatment in Phase 3 trials patients with immune thrombocytopenia ( ITP ). This report describes up to 5 years weekly romiplostim 292 adult a long‐term, single‐arm, open‐label study. Outcome measures included adverse events (including bleeding, thrombosis, malignancy, reticulin/fibrosis), platelet response (platelet count >50 × 10 9 per litre), the proportion requiring rescue treatments....
Background The risk of thromboembolic events in adults with primary immune thrombocytopenia has been little investigated despite findings increased susceptibility other thrombocytopenic autoimmune conditions. objective this study was to evaluate the among adult patients and without UK General Practice Research Database.Design Methods Using Database, 1,070 (≥18 years) coded records for first referenced between January 1st 1992 November 30th 2007, having at least one year pre-diagnosis three...
Objective. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be quite effective in the treatment of immune disorders resulting from autoantibodies. We prospectively studied long-term effects rituximab 10 patients with anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis refractory conventional therapy (n=3) or second subsequent relapse (n=7).
Summary In anecdotal reports, some patients with immune thrombocytopenia ( ITP ) maintained platelet counts after discontinuing romiplostim. Here, we examined rates of response (≥50 × 10 9 /l), remission , splenectomy and adverse events in primary duration ≤6 months who were treated romiplostim for ≤12 months. The starting dose was 1 μg/kg; concomitant rescue treatments permitted to maintain counts. Patients ≥50 /l at the end 12 entered a taper which decreased as long maintained. Remission...
Abstract Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder, characterized by a low platelet count (<100 × 10 9 /L) in the absence of other causes associated with thrombocytopenia. In most patients, IgG autoantibodies directed against receptors can be detected. They accelerate clearance and destruction, inhibit production, impair function, resulting increased risk impaired quality life. Efgartigimod human IgG1 antibody Fc‐fragment, natural ligand neonatal Fc...
Cases of de novo immune thrombocytopenia (ITP), including a fatality, following SARS-CoV-2 vaccination in previously healthy recipients led to studying its impact preexisting ITP. In this study, 4 data sources were analyzed: the Vaccine Adverse Events Reporting System (VAERS) for cases ITP; 10-center retrospective study adults with ITP receiving vaccination; and surveys distributed by Platelet Disorder Support Association (PDSA) United Kingdom (UK) Association. Seventy-seven identified...
Abstract To determine whether warm‐antibody autoimmune hemolytic anemia (AIHA) responds to treatment with intravenous gammaglobulin (IVGG), we conducted separate pilot studies at three institutions enrolling a total of 37 patients. We combined these results review 36 cases AIHA treated IVGG reported in the literature. Sixteen clinical variables were examined associations response IVGG. Overall, 29 73 patients (39.7%) responded therapy. Two strongly related good IVIG: presence hepatomegaly...
Monitoring of platelet activation by the ADVIA 120 Hematology System requires an anticoagulant and protocol that ensures platelets are sphered their status is not altered artifactually in vitro.Blood from healthy controls was collected into tripotassium EDTA; citrate, theophylline, adenosine, dipyridamole (CTAD); or a combination both (E/C) stored at ambient temperature 4 degrees C (E/C only) then analyzed between 0 180 min later on 120. In addition, immunofluorescent flow cytometry used to...
Abstract The objective of this open label, phase 1–2, multicentre trial was to evaluate the safety AMG 531, a novel thrombopoiesis‐stimulating peptibody, and its effect on platelet counts in adults with immune thrombocytopenic purpura. Four patients were assigned each four unit‐dose cohorts: 30, 100, 300 or 500 μ g, administered subcutaneously days 1 15 (or day 22 if count >50 × 10 9 /l). Safety assessed by adverse event (AE) monitoring, clinical laboratory studies antibody assays....
We conducted a retrospective analysis of 11 consecutive patients with various autoimmune cytopenias who failed to respond conventional treatments and received fixed-dose regimen rituximab (100 mg weekly for 4 weeks). Sustained complete responses were achieved in out 7 idiopathic thrombocytopenic purpura 1 patient pancytopenia. A partial response was observed hemolytic anemia. The immunotherapy had no effect pure red cell aplasia or neutropenia. No infusion-related delayed toxicities...
Summary A clinical syndrome of bleeding and purpura consistent with a diagnosis immune thrombocytopenia (ITP) was described by Werlhof long before platelets were identified as the cellular component blood playing an essential role in primary haemostasis. Although for spleen suggested nearly century ago, pathophysiology ITP has remained elusive many decades. During this time Werlhof’s disease renamed idiopathic thrombocytopenic purpura, from which acronym originally derives. The second half...